Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.

INTRODUCTION: Immunotherapy and targeted therapy have extended life expectancy in non-small cell lung cancer (NSCLC) patients, shifting it into a chronic condition with comorbidities, including osteoporosis. This study aims to evaluate the prevalence and incidence of osteoporotic vertebral fracture (OPVF) during NSCLC follow-up, identify risk factors of OPVF, and determine the impact on overall survival (OS). METHODS: We performed a longitudinal single-center retrospective cohort study involving patients with histologically proven NSCLC of any stage. Chest-abdomen-pelvis computed tomography (CAP CT) at diagnosis and during follow-up were double-blind reviewed to determine OPVF site, count, type, time to incident OPVF, and trabecular volumetric bone density (TVBD). An institutional expert committee adjudicated discrepancies. Binary logistic regression was used to predict the occurrence of incident OPVF. OS was calculated using the Kaplan-Meier method. RESULTS: We included 289 patients with a median follow-up of 29.7 months. OPVF prevalence was 10.7% at inclusion and 23.2% at the end of follow-up. Cumulative incidence was 12.5%, with an incidence rate of 4 per 100 patient-years. Median time to incident OPVF was 13 months (IQR: 6.7-21.2). Seven of the 36 patients with incident OPVF received denosumab or bisphosphonates. In multivariable analysis, independent risk factors for incident OPVF were BMI < 19 kg/m2 (OR: 5.62, 95%CI 1.84-17.20, p = 0.002), lower TVBD (OR: 0.982 per HU, 95%CI 0.97-0.99, p = 0.001) and corticosteroid use (OR: 4.77, 95%CI: 1.76-12.89, p = 0.001). OPVF was not significantly associated with OS. CONCLUSIONS: Osteoporosis should be screened for in NSCLC patients. Thoracic oncologists must broaden the use of steroid-induced osteoporosis recommendations.

[Efficacy of the oral antiparasitic mebendazole plus trichlorfon (telmin plus trichlorfon) against Gasterophilus in the horse]. / Efficacité de l'antiparasitaire oral Mebendazole plus Trichlorfon (Telmin plus Trichlorfon) contre les gastérophiles chez le cheval.

The combined drug Mebendazole plus Trichlorfon (Telmin plus Trichlorfon, Janssen Pharmaceutica, Beerse/Belgium) has been tested in a field trial against naturally acquired Gasterophilus spp. infestations in horses. 44 foals (1 to 1.5 years old, 350-450 kg body-weight) originating from different endemic areas of Switzerland, have been randomly allocated to two groups as follows: 28 foals were treated with Mebendazole plus Trichlorfon, 16 animals served as untreated controls. The drug (paste) was administered and dosed according to the user's instruction. Macroscopic examinations of the digestive tractus and the larval counting has been performed immediately after slaughtering, i.e. 30 and 33 days after treatment, resp.. The efficacy of the product against Gasterophilus spp. amounts to 97.04% which is considered as highly effective. A further proof for the high efficacy is the observation of a lot of larvae-carrying foals in the control group. Since the larvae of Gasterophilus spp.--according to their life cycle--are essentially found in their hosts between November and February, an appropriate treatment should be performed during that period of time.

[The epidemiology of gasterophilosis of horses in Switzerland]. / Approche de l'épidémiologie de la gastérophilose du cheval en Suisse.

Between March 1988 and December 1989, 198 gastrointestinal tracts from slaughtered horses from different areas of Switzerland have been analysed for the presence and the frequency of Gasterophilus spp. During the same period--always between July and November--200 horses from selected areas of Western Switzerland have been checked for the presence of eggs and their subsequent developmental stages in order to investigate further clinical and biological aspects of this infection. The evaluation has been performed according to origin, age, sex, colour of the horse and seasonal pattern of the cases and the various larval stages, respectively. The prevalence of Gasterophilus spp. amounts to 64.6%, showing a marked seasonal distribution. Only Gasterophilus intestinalis has been detected and the Western part of Switzerland appears to be considerably more contaminated than the other areas of the country. The reasons are discussed. It is possible that an intensive horse-traffic at the border is partly responsible. Horses with a dark coat are more often parasitized whereas no difference occurs with regard to age and sex. The observed high prevalence of this parasite infection in the Swiss horse population confirms that gasterophilosis has to be taken into serious consideration and prophylactic measures might be indicated.